Glaukos: Ophthalmology Specialist Sees Significant Gains After Forecast Upgrade!
Reading Time: 3 minutes
Outstanding Q2 figures: An impressive revenue increase of +49.54% to $185.61 million far exceeds analysts' estimates. Volume driver: Management has drastically raised the annual forecast, facilitating targeted accumulation by institutional investors. Future perspective: The commercial breakthrough of the groundbreaking glaucoma implant iDose TR promises long-term dynamic growth. The stock of Glaukos is currently being accumulated under extremely high trading volume, as excellent quarterly figures and a drastically raised annual...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
